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INTRODUCTION
The tripartite RANK/RANKL/OPG (receptor activator of
nuclear factor kB, its ligand, and osteoprotegerin) signalling
system plays a key role in the osteogenesis and bone
remodelling by controlling recruitment, differentiation and
function of the cells involved (1). OPG is a soluble member of
the tumour necrosis factor receptor superfamily, expressed by
cells (e.g. endothelial, vascular smooth muscle, osteoblastic)
in various organs (2-4). It acts as a decoy receptor for
RANKL, inhibiting its interaction with RANK on osteoclast
precursor cell membranes, thus preventing their osteoclastic
differentiation (1).
Recent studies suggest that calcific aortic valve stenosis
(CAVS), the most frequent non-rheumatic heart valve disease
and the main cause of valve replacement in the elderly is an
actively regulated process that involves mechanisms of bone
development (4-10). Altered expression of RANK, RANKL and
OPG was observed in native stenotic valves as well as in
calcified aortic valve allografts (10, 11). Moreover, serum levels
of OPG are elevated in patients with CAVS (12).
The aim of the present study was to assess whether serum
levels of OPG and sRANKL can be correlated with the
character of histopathological changes in the valves of the
patients with CAVS.
MATERIALS AND METHODS
Patients and tissue material
Stenotic aortic valves were obtained from patients with
CAVS (n=27) undergoing valve replacement surgery (mean age
71.56±6.37 years; 16 males, 11 females). Only tricuspid valves
without signs of infective endocarditis or rheumatic heart disease
were included to the study. Control, macroscopically normal
aortic valves (n=8) were collected upon autopsies from age- and
sex-matched individuals. In CAVS patients, serum samples for
measurements of OPG and sRANKL were collected twenty four
hours before surgery and stored at –80°C until use. The
respective controls (n=12) were serum samples collected from
age- and sex-matched patients without aortic valve disease.
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osteoclastic cells (tartrate-resistant acid phosphatase, TRAP), macrophages (CD68) and blood vessels (CD34). Patients
with CAVS had elevated levels of OPG as compared to the control group (p=0.005). Within the CAVS group, patients
with osteoclastic TRAP-positive cells in their valves had significantly lower serum levels of OPG (p=0.009) and lipid
content (p=0.03) than those without such cells. Moreover, osteogenic metaplasia was observed exclusively in the valves
containing TRAP-positive cells. Results of this study suggest that the circulating OPG can influence the processes
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preventing osteogenic metaplasia.
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Otherwise, the clinical parameters of the control group did not
significantly differ from the group of stenotic patients. The study
protocol was approved by the Bioethical Committee of the
Jagiellonian University.
Assessment of osteoprotegerin and sRANKL
The concentration of OPG in serum was measured by
multiplex Luminex technology using Human Bone Panel kit
(Millipore, USA), according to the manufacturer’s instruction.
Data were analyzed using a Flexmap 3D instrument (Luminex
xPONENT® 4.0 Software) and Luminex Analyst Program
(Luminex Corporation, Austin, Texas, USA).
The levels of sRANKL were measured using enzyme-linked
immunosorbent assay (ELISA) kit (BioVendor, Brno, Czech
Republic), according to the manufacturer’s instruction. Inter-
and intra-assay coefficients of variation of both tests were
between 7% and 11%.
Macroscopic analysis of valve cusps
The valve cusps were examined under Stemi 2000C
stereomicroscope (Zeiss, Germany) coupled to Coolpix 990
digital camera (Nikon, Japan) and PC-class computer equipped
with AnalySIS-FIVE® (Soft Imaging System GmbH, Munster,
Germany) image analysis system. The following parameters
were assessed: area of focal calcifications (measured at the aortic
side and verified by von Kossa staining), expressed as
percentage of the total cusp area, unilateral (aortic side only) or
bilateral (aortic and ventricular sides) location of calcifications,
and involvement of the cusp base (valve ring) in calcification.
Preparation of valve cups for miscoscopy
The cups of stenotic valves were dissected into two parts
along the line passing from cusp base to its free margin through
the most pronounced focal calcifications. The cusps of control
valves were likewise divided into two halves. One part/half was
fixed for 24 hours in 4% buffered paraformaldehyde, decalcified
for 4 days in 10% EDTA and routinely embedded in paraffin. Six
µm sections were mounted on polylysine-coated slides (Menzel-
Glaser; Thermo Scientific, Germany). The other part/half was
embedded in OCT (Jung, Nussloch, Germany) and frozen. Ten
µm cryostat (Jung CM1800, Leica Instruments GmbH,
Germany) sections were mounted on polylysine-coated slides,
dried in air and fixed for 5 min in 4% buffered
paraformaldehyde.
Histology and histochemistry
Deparaffinized sections were stained routinely with
hematoxylin and eosin. Frozen sections were stained with Oil
red O (ORO) to reveal lipids.
Immunohistochemistry
Deparaffinized sections were first boiled in citrate buffer
(pH 6.0) for antigen retrieval and then preincubated for 40 min
with 5% normal goat serum (Vector, Burlingame, CA; # S-1000)
in PBS containing 0.01% sodium azide, 0.05% thimerosal, 0.1%
bovine serum albumin and 0.5% Triton X-100 to reduce
nonspecific binding and to increase penetration of the
antibodies. The sections were next incubated overnight with the
primary antibodies against: tartrate-resistant acid phosphatase
(TRAP), dilution 1:50 (code no. NCL-TRAP; Novocastra,
Newcastle, UK), to visualize cells with osteoclastic
differentiation (13); CD68 antigen, dilution 1:1 (code no.
IHCR2113-6; Chemicon, Temecula, CA), a marker of clasically
activated (M1) macrophages (14); CD34 antigen, dilution 1:50
(code no. NCL-END; Novocastra, Newcastle, UK), a marker of
endothelial cells, to reveal blood vessels (15). Next, sections
were washed extensively in PBS and incubated for 90 min with
goat anti-mouse Alexa555-conjugated antibody, dilution 1:200
(code no. A-21424; Molecular Probes, Eugene, OR). Cell nuclei
were counterstained with DAPI (Sigma, Saint Louis, MO,
USA). Sections were washed three times in PBS and mounted in
glycerol/PBS solution (pH=8.6). Negative controls were
performed by omitting the primary antibodies during the first
incubation.
Microscopy and morphometry
Sections were examined under Olympus BX50 bright
field/fluorescence microscope (Olympus, Japan). Images were
recorded using DP-71 digital CCD camera (Olympus, Japan)
coupled to PC-class computer equipped with AnalySIS-FIVE®
(Soft Imaging System GmbH, Munster, Germany) image
analysis system. Sections of valves containing mono- and
multinuclear TRAP-positive cells were also examined in a laser
scanning (confocal) fluorescence microscope (FluoView FV10i,
Olympus, Tokyo, Japan). Images were collected using the FV10-
ASW v.3.00 software (Olympus, Japan).
Microvessel density and the number of CD68-positive
macrophages was assessed semiquantitatively in 10 randomly
chosen high magnification (400×) fields per valve sample
according to the following 0–3 scale:
macrophages: 0 – no cells; 1 – single cells per field; 2 – up
to 3 cell groups or numerous single cells per field; 3 – numerous
cell groups per field;
blood vessels: 0 – no blood vessels; 1 – 1-3 vascular profiles
per field; 2 – 4-10 vascular profiles per field; 3 – >10 vascular
profiles per field.
The area occupied by ORO-stained lipids was measured
using the image analysis system and expressed as percentage of
the total cusp section area.
Statistical analysis
The variables were expressed as mean ± S.D. or median
(lower-upper quartile values) depending on their type and
distribution. The Kolmogorov-Smirnov test was used to access
conformity with a normal distribution. The statistical analysis
included (in compliance with the specific category of collected
data) t-Student test for unpaired data, Mann-Whitney U test, and
c2 or Fisher’s exact tests. The one-way ANOVA (followed by the
Newman-Keuls post hoc test) or Kruskal-Wallis tests were used
for multiple group comparison. Stepwise multivariate logistic
regression analysis was performed to test whether the level of
circulating OPG is a predictor of the valvular TRAP positive
cells. Age, gender and serum sRANKL, were tested as potential
covariates. Statistical analyses were performed using
Statgraphics 5.1 Plus for Windows (Statpoint Technologies INC,
Warrenton, USA) software. In all tests two-tailed p values <0.05
were considered statistically significant.
RESULTS
Histopathological examination
Microscopic examination of valve sections revealed more or
less extensive focal calcifications in all stenotic valves and in 4
cases osteogenic metaplasia (bone trabeculae). Cells positive for
TRAP (an enzyme expressed by cells undergoing osteoclastic
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differentiation) were found in 14 (51.9%) stenotic valves; no such
cells were observed in the control valves (Fig. 1). These cells were
mostly mononuclear, large multinuclear cells with typical
osteoclastic morphology were found in valves of 4 (14.8%)
patients. TRAP-positive cells were predominantly located in the
vicinity of focal calcifications and in cases of valvular osteogenic
metaplasia on the surfaces of bone trabeculae. All valves with
osteogenic metaplasia contained TRAP-positive cells. CD68-
positive macrophages also showed preferential location associated
with focal calcifications, however, their distribution was more
uniform, with relatively numerous cells located in non-affected
parts of fibrosa and spongiosa. In the control valves, their number
was significantly lower than in the stenotic valves (p=0.02). Blood
vessels (mostly capillaries and just a few arterioles and venules)
were observed close to focal calcifications in 20 (74.1%) stenotic
valves and were absent from control valves. In stenotic valves,
lipid deposits were located inside and in the vicinity of focal
calcifications; lipid-rich strands of tissue were also observed in the
superficial layer of fibrosa in other valve areas (Fig. 2). The
control valves showed only trace lipid content: lipid-occupied area
>1% was found only in two valves.
Circulating osteoprotegerin level influences osteoclastic
differentiation in calcified aortic valves
Serum levels of OPG were significantly higher in patients
with CAVS than in the control group (0.41±0.16 ng/ml vs
0.25±0.12 ng/ml; p=0.005), while no significant difference was
found in case of sRANKL (126.1 [87.75-155.7] pmol/l vs 134.8
[89.36-235.2] pmol/l; p=0.5).
We examined the relation between OPG and sRANKL
serum levels of CAVS patients and the histological parameters of
their valves. The only significant association was observed in
case of OPG and the presence or absence of TRAP-positive
cells: significantly lower OPG serum concentration (p<0.01),
comparable to that of the control group, was found in patients,
whose valves contained such cells (Fig. 1).
Stepwise multivariate logistic regression analysis was
performed to evaluate OPG as a predictor of the occurrence of
valvular TRAP-positive cells. Age, gender and serum
sRANKL (factors known to be related to calcification/
ossification processes) were tested as potential covariates.
OPG was the only variable predictive for the TRAP-positive
cells (Table 1).
Then we checked whether the difference in the content of
TRAP-positive cells between the patients with aortic stenosis is
correlated with differences in the histopathological parameters
of their valves (Table 2). Significant differences between the
groups with and without TRAP-positive cells were observed in
the presence of continuity between cusp and valve ring
calcifications and in abundance of lipid deposits (Fig. 2). The
presence of TRAP-positive cells was negatively correlated with
the lipid content in the valves and positively correlated with
valve ring calcification.
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Fig. 1. Representative micrographs showing TRAP-positive cells in the stenotic valve of a patient with low OPG level (A) and their
absence in the stenotic valve of a patient with high OPG level (B) and in the normal control valve (C). Both mononuclear and
multinuclear TRAP-positive cells with typical osteoclastic morphology (D, the area framed in A imaged in a laser scanning
microscope) were observed in the stenotic valves. Asterisks: focal calcifications. Bars = 10 µm (A-C) and 50 µm (D). Serum OPG (E)
and sRANKL (F) levels in CAVS patients with and without TRAP-positive cells in stenotic aortic valves and in control individuals.
E: mean ±S.D., F: box and whisker plot showing median, interquartile range and outliers. **p<0.01; ***p<0.001.
DISCUSSION
The calcific aortic valve stenosis (CAVS) is now widely
regarded as an active biological process involving mechanisms
similar to osteogenesis. Calcification of the valve is associated
with the appearance of osteoblast-like cells expressing markers
found also in skeletal osteoblasts (8, 16). Mononuclear and
multinuclear cells showing osteoclastic differentiation are also
observed in calcifying human valves (5, 17, 18). Hence, the
involvement of the RANK/RANKL/OPG signalling system in
the pathogenesis of CAVS has been postulated (19). Moreover,
OPG, as a decoy receptor for TNF-related apoptosis-inducing
ligand (TRAIL) (20), can also influence calcification of the
valves via its interaction with TRAIL which was recently
demonstrated to show high expression in calcific valves and to
promote matrix synthesis and mineralization in cultured valvular
interstitial cells (21).
We could not observe any relation between the occurrence of
TRAP-positive cells and the area of calcification in the valve,
although calcification of the valve ring was mostly associated
with the presence of such cells. Moreover, true bone formation
was found only in the valves that contained TRAP-positive cells.
This might suggest that inhibited osteoclastic differentiation in
the valve acts towards preventing osteogenic metaplasia and
restricting the expansion of the calcification process in the valve.
The concept that osteoclastic differentiation is important for
osteogenic metaplasia is in line with results recently published
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Fig. 2. Representative micrographs of ORO-stained lipids in the valves of CAVS patients with (A) and without TRAP-positive cells
(B). Bars = 500 µm. C: content of ORO-stained lipids in the valves of CAVS patients with and without TRAP-positive cells (% s.a. –
percent of the surface area). *p<0.05.
Variable* Beta SE p value
Age 0.09 0.07 0.214
OPG –8.97 3.76 0.004
*Variables considered for entry into the model: age, gender,
serum OPG, serum sRANKL.
Table 1. Multivariate logistic regression model for the
occurrence of TRAP-positive cells in valves.
Variable TRAP + (n=14) TRAP – (n=13) p Value
Focal calcifications (% area) 42.91 ± 15.5 39.23 ± 17.24 0.6 
Involvement of valve ring 12 (85.7) 5 (38.5) 0.02
Bilateral calcifications 3 (21.4) 1 (7.7) 0.6
Osteogenic metaplasia 4 (28.6) 0 (0) 0.1
Macrophages (0–3) 2 [2–3] 2 [1–2] 0.1
Blood vessels (0–3) 2 [1–3] 1 [0–2] 0.1
Lipids (% section area) 22.35 ± 6.88 30.46 ± 10.68 0.03 
Values are expressed as mean ±S.D., median [lower-upper quartile] or number (%) of patients.
Table 2. Comparison of histopathological parameters of the valves in CAVS patients with and without TRAP-positive cells.
by Chai et al. (22), who reported that in vivo ectopic bone
formation is associated with osteoclastogenesis and osteoclastic
activity.
Lipid accumulation was significantly lower in the valves
with TRAP-positive cells. The neutral lipids detected by ORO
staining are mostly oxidized LDLs (23). Enhanced content of
LDLs in the valves of patients with elevated serum OPG and the
reported effect of statins which were found to lower serum OPG
level in patients with CAVS and carotid stenosis indicate a
possible link between OPG and lipid accumulation in the
stenotic valves (24, 25).
The main and to the best of our knowledge novel finding of
this study is that elevated levels of circulating OPG is associated
with inhibited osteoclastic differentiation in calcifying aortic
valves. Recruitment of monocytes, precursors of macrophages
and osteoclasts, to areas of atherosclerosis and calcification is
controlled by several factors (26). The inhibition of osteoclast
differentiation and recruitment is a well known effect of OPG in
the skeletal system, but it remains unclear how it influences the
local calcification process in the valve (1). On one hand,
deficiency of osteoclasts which are capable of mineral resorption
in bone and atherosclerotic arteries should promote calcification
of the valve (27). On the other hand, in hypercholesterolemic
mice OPG was demonstrated to attenuate pro-calcific processes
in aortic valves (28). Moreover, in the animal model of
atherosclerosis, which shares many features with calcific valve
degeneration, OPG inhibits calcification. Mice deficient in both
OPG and apolipoprotein E (ApoE) had larger calcified
atherosclerotic lesions as compared to ApoE-knockout animals
(29). Administration of recombinant osteoprotegerin to ldlr-
deficient mice fed atherosclerotic diet reduced the size of
calcified lesion area (30). Denosumab, an anti-RANKL antibody
mimicking the action of OPG, reduced calcium deposition in
aortic wall of glucocorticoid-treated human RANKL knock-in
mice (31). In contrast, human studies provided some evidence of
an opposite effect of OPG: high circulating OPG levels were
demonstrated to enhance the severity and 10-year progression of
carotid atherosclerosis and to enhance the severity of aortic
calcification in hemodialysis patients (32, 33).
OPG and RANKL are also expressed in the valvular tissue
and in myocardium, so local paracrine effects of these factors
can not be excluded. However, an increased local expression of
OPG and RANKL was observed in damaged myocardium of
patients with myocardial infarction developing heart failure (34),
in non-ischemic dilated cardiomiopathy (35) or in atrial
fibrillation (36). In CAVS, most authors reported low or no
expression of OPG in the calcified human valves (10, 11, 37),
while OPG expression in myocardium seems to be a secondary
effect, since myocardium and peripheral tissues can extract OPG
and other factors from the circulation (38, 39). A contradictory
result was reported by Pohjolainen et al. (7) who studied a wide
spectrum of aortic valves from normal to heavily calcified and
found progressive elevation of OPG gene expression and
immunohistochemically detectable OPG content in the valves.
Irrespective of this controversy, it seems that not only locally
produced, but also circulating OPG can contribute to the
calcification process in the valve (28).
In view of reports showing that drug therapies tested in
CAVS (24) or used in other pathologies (25, 40, 41) may directly
or indirectly influence serum OPG level, our observation can
also be clinically relevant, although so far it is not clear whether
the modification of the local valvular milieu by OPG reported in
this study is beneficial or detrimental for CAVS patients.
In conclusion, our results suggest that elevated circulating
OPG in patients with calcific aortic valve stenosis is associated
with the inhibition of local osteoclastogenesis and osteogenic
metaplasia in the stenotic valves. This aspect of OPG action
should also be taken under consideration in planning treatment
strategies that influence the RANK/RANKL/OPG system.
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